Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

About this update from Forte Biosciences, Inc.

[{"type":"text","content":"FB102 Received Fast Track Designation in Celiac Disease","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"DALLAS, May 11, 2026--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update.","length":286,"tagName":"p"},{"type":"text","content":""FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly," said Forte Biosciences CEO Paul Wagner, PhD. "The topline results from our phase 2 celiac disease study are expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is expected to have topline results shortly and the alopecia areata phase 1b data readout is expected in 2026. We remain very optimistic about FB102’s potential to address the significant unmet medical needs across multiple indications representing what we believe to be multi-billion-dollar potential market opportunities."","length":1010,"tagName":"p"},{"type":"text","content":"Q1 2026 Operating Results","length":25,"tagName":"p","attribs":{}},{"type":"text","content":"Research and development expenses were $20.5 million for the three months ended March 31, 2026, compared to $12.7 million for the same period in 2025. The increase was primarily due to an increase of $6.7 million in clinical expenses related to FB102 for our Phase 2 clinical trial for celiac disease and Phase 1b clinical trials for vitiligo and alopecia areata, an increase of $2.0 million in preclinical expenses, and an increase of $1.4 million in personnel-related expenses due to an increase in headcount, partially offset by a decrease of $2.3 million in manufacturing expenses.","length":585,"tagName":"p"},{"type":"text","content":"Our research and development expenses may increase as we continue to advance FB102 through a celiac Phas...

More updates from Forte Biosciences, Inc.